MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9600
+0.1221
+14.57%
Pre Market: 0.9944 +0.0344 +3.58% 08:22 06/02 EDT
OPEN
0.9900
PREV CLOSE
0.8379
HIGH
1.060
LOW
0.9020
VOLUME
2.36M
TURNOVER
--
52 WEEK HIGH
5.53
52 WEEK LOW
0.5500
MARKET CAP
10.04M
P/E (TTM)
-0.3635
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRPO stock price target is 4.150 with a high estimate of 6.30 and a low estimate of 2.000.

EPS

PRPO News

More
Pandemic Damage And The Vaccine Industry
Seeking Alpha - Article · 05/26 10:46
Sanofi Partner Takes On Vaccine Hurdle: Minus-112 Degree Storage
bloomberg.com · 05/20 14:21
Precipio, Inc. to Host Earnings Call
ACCESSWIRE · 05/19 20:00
Tracking Seth Klarman's Baupost Group Holdings - Q1 2020 Update
Seeking Alpha - Article · 05/18 09:48
Precipio EPS misses by $0.59, misses on revenue
Precipio (NASDAQ:PRPO): Q1 GAAP EPS of -$0.78 misses by $0.59. Revenue of $1.22M (+71.8% Y/Y) misses by $1.08M. Press Release
seekingalpha · 05/15 19:17
Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M
GlobeNewswire · 05/15 15:00
Precipio Q1 Net Sales Up 77% From Last Qtr. To $1.2M
Benzinga · 05/15 14:02
Precipio Announces Q1-2020 Corporate Update Call For Shareholders
GlobeNewswire · 05/12 22:00

Industry

Advanced Medical Equipment & Technology
+0.58%
Healthcare Equipment & Supplies
+0.10%

Hot Stocks

Symbol
Price
%Change

About PRPO

Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
More

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.